Exploring gene-drug associations is a key step in identifying new drug candidates, but traditional experimental methods are often expensive and time-consuming. While Graph Neural Network (GNN)-based ...

Our findings establish FOXK2 as a novel pathogenic gene in congenital myopathy associated with ptosis, highlighting its previously unrecognized role in skeletal muscle development. These results ...

In addition, we show that the C-terminal SH3 domain binding to a polyproline region N-terminal to the DH domain of the Tim subgroup of Dbl-family proteins provides a unique mechanism of regulated ...

In vitro studies of the binding of either isolated or linked CIN85 SH3 domains provide an important insight into the mechanism of recognition and recruitment of Cbl proteins to these domains.

Bootstrap Bio has hired a chief science officer, opened a lab and sought seed funding to edit human cells that can be passed to future generations ...

Google's DeepMind launches AlphaGenome, an artificial intelligence model that predicts gene expression from DNA sequence.

In this study of an AAV9-based gene therapy in four patients with infantile-onset Pompe’s disease, one patient died and one had pneumonia that led to the temporary administration of oxygen ...

Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that predicts what effects small changes in DNA will have on an array of ...

Many DNA sequences, for example, influence gene activity by altering a chromosome’s 3D shape, either restricting or easing access for the machinery that does the transcription.

Scientists Advance Prospects for Permanently Putting AIDS Virus into Dormant State Using Gene Therapy 06/25/2025 ...

Sangamo's investigational gene therapy has been tied to an improvement in kidney health deterioration at 52 weeks for patients with Fabry disease.

The 14-gene assay identified patients with molecular high risk who benefitted from adjuvant chemotherapy. Use of the assay to determine eligibility for adjuvant therapy in stage IA–IIA non-squamous ...